Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2025, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $240.68 million, up 8.5% over the same period last year. EPS came in at -$0.48, compared to -$0.47 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $238.61 million, representing a surprise of +0.87%. The company delivered an EPS surprise of -20%, with the consensus EPS estimate being -$0.40.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Pump Shipments - Total Worldwide: 30,000 compared to the 30,679 average estimate based on two analysts.Pump Shipments - Outside the United States: 9,000 versus 9,093 estimated by two analysts on average.Pump Shipments - United States: 21,000 versus 21,586 estimated by two analysts on average.Sales- Pump- United States: $85.47 million versus $91.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.Geographic Sales- Outside the United States: $70.47 million compared to the $65.57 million average estimate based on four analysts. The reported number represents a change of +8.1% year over year.Sales- Supplies and Other- Outside the United States: $44.07 million versus the four-analyst average estimate of $41.64 million. The reported number represents a year-over-year change of +12.8%.Sales- Pump- Outside the United States: $26.4 million compared to the $23.93 million average estimate based on four analysts. The reported number represents a change of +1.1% year over year.Sales- Supplies and Other- United States: $84.74 million versus $80.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.3% change.Geographic Sales- United States: $170.21 million versus the three-analyst average estimate of $173.34 million. The reported number represents a year-over-year change of +8.6%.Revenue- Supplies and Other: $128.81 million compared to the $122.4 million average estimate based on five analysts.Revenue- Pump: $111.87 million versus the five-analyst average estimate of $115.69 million.View all Key Company Metrics for Tandem Diabetes Care here>>>Shares of Tandem Diabetes Care have returned -8.8% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks